Dimethyl Sulfoxide
Medchemexpress LLC 10 MM 1 ML IN DMSO READY 1MM
10 mM * 1 mL in DMSO ready for reconstitution, 1Mm, 2883540-92-7
Medchemexpress LLC Afatinib 10Mm 1Ml/Dmso Reconst | HY-10261-10MM 1ML RECONS
Afatinib 10Mm 1Ml/Dmso Reconst
Apexbio Technology LLC YM201636 371942-69-7 10mM (in 1mL DMSO)
YM201636 is a cell-permeable selective inhibitor of the mammalian class III phosphatidylinositol phosphate kinase PIKfyve It functions by targeting and inhibiting PIKfyve enzymatic activity at an IC50 of approximately 33 nM thus reducing the biosynthesis of phosphatidylinositol (3 5)-bisphosphate (PtdIns(3 5)P2) Treatment of various mammalian cell lines (including NIH3T3 MDCK MCF10A COS7 and MEFs) with YM201636 induces the formation of enlarged intracellular vacuoles pointing toward changes in endosomal transport and membrane trafficking Furthermore YM201636 has shown utility in studying insulin-mediated signaling by inhibiting insulin-dependent class I PI3K activation lowering Akt phosphorylation and preventing surface translocation of GLUT4 in adipocytes Researchers frequently utilize this compound to analyze intracellular vesicular transport pathways and phosphoinositide-dependent signaling events
Apexbio Technology LLC ICG 001 847591-62-2 10mM (in 1mL DMSO)
ICG 001 is a small molecule inhibitor of the canonical Wnt/ -catenin signaling pathway Mechanistically it competes with -catenin for interaction with CREB-binding protein (CBP) thereby selectively disrupting CBP/ -catenin-mediated transcriptional activity driven by the TCF/ -catenin complex (IC50 3 M) Experimental studies demonstrated its use in assessing CBP-dependent biological functions regulated by Wnt signaling Research applications include investigating CBP/ -catenin roles in cancer cell proliferation such as colorectal cancer cells (HCT-116 SW480) glioblastoma stem cell growth and fibrotic responses in pulmonary and dermal experimental models Additionally ICG 001 is under evaluation in clinical studies aiming at treatment of colorectal cancer and leukemia
Apexbio Technology LLC Mirabegron (YM178) 223673-61-8 10mM (in 1mL DMSO)
Mirabegron (YM178 CAS 223673-61-8) is a selective agonist targeting the -adrenergic receptor ( -AR) Activation of -AR influences physiological responses in tissues including adipose cells prostate gastrointestinal tract and primarily the urinary bladder In CHO cells expressing human -adrenergic receptor subtypes mirabegron demonstrated selective agonist properties at -AR (EC 22 4 nM) showing minimal activity at - and -AR subtypes Animal studies revealed mirabegron reduced rhythmic bladder contraction frequency without affecting amplitude Its selective -AR agonist profile makes mirabegron pertinent for research on bladder dysfunction particularly overactive bladder conditions
Apexbio Technology LLC Febuxostat 144060-53-7 10mM (in 1mL DMSO)
Febuxostat (CAS 144060-53-7) is a non-purine selective inhibitor of xanthine oxidase (XO) an enzyme involved in purine metabolism responsible for producing uric acid and reactive oxygen species (ROS) It exerts its inhibitory action by noncompetitive binding at the molybdenum-pterin active center of XO effectively inhibiting both its oxidized and reduced forms Compared to allopurinol febuxostat demonstrates notably higher potency with a reported IC50 of 1 8 nM versus 2 9 M Febuxostat is utilized in clinical and preclinical research exploring hyperuricemia gout and associated metabolic disorders
Apexbio Technology LLC PD123319 130663-39-7 10mM (in 1mL DMSO)
PD123319 (CAS 130663-39-7) is a non-peptide antagonist targeting angiotensin II (Ang II) receptors particularly the AT2 receptor subtype It binds selectively exhibiting an IC50 of 34 nM in rat adrenal assays and 210 nM in rat brain binding assays Additionally PD123319 inhibits Ang II binding to bovine adrenal glomerulosa microsomal preparations with an IC50 of 6 9 nM Its antagonistic activity leads to reduced cyclic GMP synthesis and elevated prostaglandin E2 production without altering protein tyrosine phosphorylation or thymidine incorporation mediated by Ang II PD123319 serves as a useful pharmacological tool in investigating Ang II receptor signaling pathways
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide suitable for HPLC, >=99.7% | 67-68-5 | MFCD00002089 | 20L
Dimethyl sulfoxide suitable for HPLC, >=99.7% | Purity: >=99.7% | Mol Wt: 78.13 | 67-68-5 | MFCD00002089 | 20L
Apexbio Technology LLC LDC1267 1361030-48-9 10mM (in 1mL DMSO)
LDC1267 (CAS 1361030-48-9) is a selective inhibitor of the TAM receptor tyrosine kinases Mer Tyro3 and Axl demonstrating IC50 values of less than 5 nM 8 nM and 29 nM respectively By inhibiting TAM signaling LDC1267 abolishes Gas6-mediated suppression in NKG2D-activated natural killer (NK) cells thus enhancing NK-mediated cytotoxicity Preclinical studies show reduced metastasis of melanoma and 4T1 breast tumor cells upon LDC1267 administration in mouse models an effect reliant on NK cell function LDC1267 provides a research tool for investigating TAM-regulated immune modulation in cancer models
Apexbio Technology LLC WZ4003 1214265-58-3 10mM (in 1mL DMSO)
WZ4003 (CAS 1214265-58-3) is a selective inhibitor targeting NUAK1 and NUAK2 kinases members of the AMP-activated protein kinase (AMPK) family activated by tumor suppressor kinase LKB1 WZ4003 inhibits NUAK1 and NUAK2 with IC50 values of 20 nM and 100 nM respectively In cellular assays treatment with WZ4003 reduces NUAK1-mediated phosphorylation of MYPT1 at Ser445 It suppresses cell proliferation migration of mouse embryonic fibroblasts and invasion of U2OS cells Thus WZ4003 serves as a valuable tool for investigating NUAK kinase functions in cell proliferation mobility and signaling mechanisms relevant to oncology research
Apexbio Technology LLC Flutamide 13311-84-7 10mM (in 1mL DMSO)
Flutamide is a synthetic nonsteroidal antiandrogen agent commonly employed in biomedical research and clinical oncology Its pharmacological activity is mediated through competitive antagonism at the androgen receptor (AR) whereby its active metabolite interacts specifically with AR exhibiting a receptor binding affinity at a K sub i /sub value around 55 nM By interfering with androgen signaling pathways flutamide inhibits AR-mediated transcriptional activity resulting in reduced cellular proliferation particularly in androgen-dependent tissues In research contexts this compound is frequently utilized to investigate AR-mediated cell biology androgen-dependent tumor development and as a pharmacological tool in model systems studying prostate cancer biology and therapeutic resistance mechanisms
Sigma Aldrich Fine Chemicals Biosciences Dimethyl sulfoxide, 67-68-5, MFCD00002089, 100mL
Linear Formula (CH3)2SO, ≥99.5% (GC), Molecular Weight 78.13, plant cell culture tested, Synonym: DMSO
Apexbio Technology LLC Propylthiouracil 51-52-5 10mM (in 1mL DMSO)
Propylthiouracil is a thioureylene derivative characterized by inhibitory effects on thyroid hormone synthesis through targeting thyroid peroxidase (TPO) and type 1 iodothyronine deiodinase (DIO1) Its mechanistic actions involve suppression of TPO activity disrupting iodine oxidation and subsequent thyroid hormone formation as well as inhibition of peripheral thyroid hormone conversion via decreased DIO1 enzymatic activity In biomedical research Propylthiouracil is commonly utilized to investigate molecular pathways underlying hyperthyroid conditions such as Graves disease as well as to experimentally explore metabolic regulation of thyroid hormones
Apexbio Technology LLC Fruquintinib(HMPL-013) 1194506-26-7 10mM (in 1mL DMSO)
Fruquintinib (HMPL-013 CAS 1194506-26-7) is a small molecule inhibitor targeting VEGFR family receptor tyrosine kinases (VEGFR1 VEGFR2 and VEGFR3) It demonstrates potent inhibitory activity with reported IC50 values of approximately 33 nM (VEGFR1) 35 nM (VEGFR2) and 0 5 nM (VEGFR3) Kinase selectivity screening indicates limited off-target effects against other kinases such as RET FGFR-1 and c-kit In preclinical tumor xenograft studies (e g gastric cancer BGC-823 model) significant tumor growth suppression ( 80%) was achieved at sustained therapeutic exposure Fruquintinib is currently under clinical investigation for cancer treatment based on its selective VEGFR pathway inhibition